AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9372290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-strategy model (reactive and predictive strategies)
Number of subjects: 2614
Study 1534001 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IFN gamma (rhIFN gamma)
Number of subjects: 14
Study 1534001 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 30506961 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMax 3D Max with low mode artefact reduction (AR)
Number of subjects: 40
Study 30506961 — intervention group
Group type: COMPARATOR
Intervention: ProMax 3D Max without artefact reduction
Number of subjects: 40
Study 30506961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pax Flex 3D
Number of subjects: 40
Study 30506961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentri S
Number of subjects: 40
Study 28072660 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HF-rTMS (2 sessions per day)
Number of subjects: 98
Study 28072660 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HF-rTMS (1 session per day)
Number of subjects: 98
Study 28072660 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (1 session per day)
Number of subjects: 98
Study 28072660 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (2 sessions per day)
Number of subjects: 98
Study 26579629 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy for anxiety
Number of subjects: 73
Study 23825078 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced muscle damage (EIMD)
Number of subjects: 10
Study 23825078 — intervention group
Group type: COMPARATOR
Intervention: Non-muscle-damaging flat run (CON)
Number of subjects: 10
Study 22827782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose zinc supplementation (50 mg elemental Zn sulfate daily)
Number of subjects: 60
Study 22827782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 60
Study 22827782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose zinc supplementation
Number of subjects: 60
Study 19851126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 252
Study 19851126 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 252
Study 17300591 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors (e.g., vildagliptin, sitagliptin)
Number of subjects: 0
Study 16392769 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid supplements (1,800 mg/day)
Number of subjects: 84
Study 16392769 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy (control group)
Number of subjects: 84
Study 11979054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg cortisol intravenously
Number of subjects: 20
Study 11979054 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 20
Study 11477843 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuanglian Powder (SHLP)
Number of subjects: 62
Study 11477843 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 62
Study 8584966 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated back spoiler mechanism
Number of subjects: 10
Study 8584966 — intervention group
Group type: COMPARATOR
Intervention: Blocked back spoiler mechanism
Number of subjects: 10
Study 2547408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 8
Study 2547408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 8
Study 2547408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 799987 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 20
Study 799987 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 30762735 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA/PCIA
Number of subjects: 100
Study 30762735 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA/PCEA
Number of subjects: 100
Study 30762735 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA-IVA/PCIA
Number of subjects: 100
Study 30762735 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA-IVA/PCEA
Number of subjects: 100
Study 30762735 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA groups
Number of subjects: 100
Study 30762735 — intervention group
Group type: COMPARATOR
Intervention: PCIA groups
Number of subjects: 100
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 60 sessions
Number of subjects: 565
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 90 sessions
Number of subjects: 565
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 60 sessions
Number of subjects: 565
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 90 sessions
Number of subjects: 565
Study 29548729 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group (Group A)
Number of subjects: 565
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: UGIB rates in Groups B and C
Number of subjects: 565
Study 29548729 — intervention group
Group type: EXPERIMENTAL
Intervention: UGIB rates in Groups D and E
Number of subjects: 565
Study 26912230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-calling participants before the 8-month follow-up questionnaire (Study 1)
Number of subjects: 609
Study 26912230 — intervention group
Group type: COMPARATOR
Intervention: Research team photograph sent with the 12-month questionnaire (Study 2)
Number of subjects: 609
Study 26912230 — intervention group
Group type: COMPARATOR
Intervention: Action-oriented email reminder ('ACTION REQUIRED') for the 12-month questionnaire (Study 3)
Number of subjects: 609
Study 25280524 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced diaphragmatic breathing (DB) training
Number of subjects: 60
Study 25280524 — intervention group
Group type: COMPARATOR
Intervention: Control condition focusing on environmental awareness
Number of subjects: 60
Study 23034059 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention promoting electronic prompts for stroke secondary prevention
Number of subjects: 0
Study 23034059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 19244039 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer
Number of subjects: 176
Study 17325899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone 80 mg/m2, methylprednisolone 500 mg, cisplatin 25 mg/m2, cytarabine 2000 mg/m2
Number of subjects: 19
Study 15049795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1, 3, 9, or 15 mg/m(2))
Number of subjects: 32
Study 15049795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11875681 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% nitroglycerin topically (administered in two daily applications for two weeks)
Number of subjects: 43
Study 11875681 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (placebo)
Number of subjects: 43
Study 9667801 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units (MU) three times per week for 6 months
Number of subjects: 255
Study 9667801 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units (MU) three times per week for 12 months
Number of subjects: 255
Study 9667801 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units (MU) three times per week for 6 months
Number of subjects: 255
Study 7774300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline pleurodesis (TCP)
Number of subjects: 78
Study 7774300 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 78
Study 7774300 — intervention group
Group type: COMPARATOR
Intervention: Tube thoracostomy alone
Number of subjects: 78
Study 7774300 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 78
Study 2925704 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stabilization of femoral fractures
Number of subjects: 178
Study 2925704 — intervention group
Group type: COMPARATOR
Intervention: Delayed stabilization of femoral fractures
Number of subjects: 178
Study 31881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Advance Directives (PAD)
Number of subjects: 400
Study 31881954 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 400
Study 28629540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OXT) at a dose of 24 international units, administered 45-70 minutes prior to testing
Number of subjects: 116
Study 28629540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 116
Study 25281353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomisation analysis using SNPs related to 25(OH)D synthesis and metabolism.
Number of subjects: 104488
Study 25281353 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of observational studies (8492 cases, 89,698 non-cases).
Number of subjects: 104488
Study 25281353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomisation analysis for glycaemic traits.
Number of subjects: 104488
Study 23318811 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Proseal (LMAP)
Number of subjects: 120
Study 23318811 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Supreme (LMAS)
Number of subjects: 120
Study 21084392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial ghrelin infusion (4.2 ng × kg(‐1) × min(‐1))
Number of subjects: 8
Study 21084392 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial placebo infusion
Number of subjects: 8
Study 19335977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil for 48 weeks
Number of subjects: 120
Study 19335977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil in combination with lamivudine for the first 12 weeks and adefovir dipivoxil only for the following 36 weeks
Number of subjects: 120
Study 19335977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil in combination with lamivudine for 48 weeks
Number of subjects: 120
Study 19335977 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir for 48 weeks
Number of subjects: 120
Study 17602082 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (CE): one cycle of cisplatin 100 mg/m2, etoposide 375 mg/m2, and ifosfamide 6 g/m2 plus three cycles of high-dose carboplatin 1,500 mg/m2 and etoposide 1,500 mg/m2
Number of subjects: 216
Study 17602082 — intervention group
Group type: COMPARATOR
Intervention: Sequential high-dose chemotherapy (CEC): three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m2, etoposide 1,800 mg/m2, and cyclophosphamide 6,400 mg/m2
Number of subjects: 216
Study 15910203 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.25 mg/kg body weight
Number of subjects: 44
Study 15910203 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg body weight
Number of subjects: 44
Study 15910203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12111764 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg PO and diphenhydramine 25 mg IV
Number of subjects: 51
Study 12111764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10533975 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 64
Study 10533975 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 64
Study 7473375 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 551
Study 7473375 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DOTA
Number of subjects: 551
Study 7473375 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA‐BMA
Number of subjects: 551
Study 2037709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg/d
Number of subjects: 16
Study 2037709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6267142 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-infected monocytes
Number of subjects: 2
Study 6267142 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte depletion
Number of subjects: 2
Study 6267142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte responses to concanavalin A (con A)
Number of subjects: 2
Study 6267142 — intervention group
Group type: COMPARATOR
Intervention: Uninfected monocytes
Number of subjects: 2
Study 31163689 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mixture (700 mg daily)
Number of subjects: 60
Study 31163689 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mixture (700 mg daily) along with Clomiphene Citrate (CC) (50-150 mg for 3 months)
Number of subjects: 60
Study 31163689 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) (50-150 mg for 3 months)
Number of subjects: 60
Study 28586828 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced milieu teaching with phonological emphasis (EMT+PE)
Number of subjects: 19
Study 28586828 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (BAU)
Number of subjects: 19
Study 25961147 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 173
Study 25961147 — intervention group
Group type: COMPARATOR
Intervention: Social Behavior and Network Therapy (SBNT)
Number of subjects: 173
Study 25961147 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist WAI
Number of subjects: 173
Study 23828457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 44
Study 23828457 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 44
Study 22011274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-gastric suture (GGS) for band fixation (Group 1)
Number of subjects: 80
Study 22011274 — intervention group
Group type: COMPARATOR
Intervention: No gastro-gastric suture (Group 2)
Number of subjects: 80
Study 19267775 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide-PR (10 mg daily for 4 days)
Number of subjects: 16
Study 19267775 — intervention group
Group type: COMPARATOR
Intervention: Torasemide-IR (10 mg daily for 4 days)
Number of subjects: 16
Study 17077394 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach intervention
Number of subjects: 456
Study 17077394 — intervention group
Group type: COMPARATOR
Intervention: Direct mail approach (Control)
Number of subjects: 456
Study 14984448 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 78
Study 14984448 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 78
Study 11297201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 87
Study 11297201 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 87
Study 9469236 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 9469236 — intervention group
Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 0
Study 9469236 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0
Study 7715469 — intervention group
Group type: EXPERIMENTAL
Intervention: Climen (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 38
Study 7715469 — intervention group
Group type: COMPARATOR
Intervention: Prempak-C (0.625 mg conjugated equine estrogens and 0.15 mg norgestrel)
Number of subjects: 38
Study 7715469 — intervention group
Group type: EXPERIMENTAL
Intervention: Climen
Number of subjects: 38
Study 7715469 — intervention group
Group type: COMPARATOR
Intervention: Prempak-C
Number of subjects: 38
Study 3145752 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 191
Study 3145752 — intervention group
Group type: COMPARATOR
Intervention: 60 mg terfenadine twice daily
Number of subjects: 191
Study 29429612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg once daily (or 5 mg once daily for patients with creatinine clearance 40 to 60 mL/min)
Number of subjects: 0
Study 29429612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29429612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 28651417 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially-assigned person rehabilitation group (SAPR)
Number of subjects: 44
Study 28651417 — intervention group
Group type: COMPARATOR
Intervention: Propaganda education rehabilitation group (PER)
Number of subjects: 44
Study 26192892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg QD for 4 weeks in IMs
Number of subjects: 42
Study 26192892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg QD for 4 weeks in PMs
Number of subjects: 42
Study 26192892 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg QD for at least 4 weeks in EMs
Number of subjects: 42
Study 23558370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40
Study 23558370 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 40
Study 21546601 — intervention group
Group type: COMPARATOR
Intervention: Cybertutor + Contact Group (Cy+C)
Number of subjects: 148
Study 21546601 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Control)
Number of subjects: 148
Study 21546601 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure Group (Br)
Number of subjects: 148
Study 21546601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybertutor Group (Cy)
Number of subjects: 148
Study 19287905 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) at 50-80% of one-repetition maximum (1-RM)
Number of subjects: 35
Study 19287905 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity general training (LGT)
Number of subjects: 35
Study 19287905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 35
Study 16734584 — intervention group
Group type: EXPERIMENTAL
Intervention: subgingival chlorhexidine varnish
Number of subjects: 12
Study 16734584 — intervention group
Group type: COMPARATOR
Intervention: same-day full-mouth root planing
Number of subjects: 12
Study 15545844 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 100
Study 15545844 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 100
Study 11396752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus fosfomycin (2 g fosfomycin twice daily for 5 days)
Number of subjects: 13
Study 11396752 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 13
Study 9430254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide at 100 mg/day for 24 weeks
Number of subjects: 19
Study 9430254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8487053 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 administered as a 100 mg/m2 weekly intravenous infusion or 150 mg/m2 every 2 weeks
Number of subjects: 67
Study 3390053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 20
Study 3390053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 30802208 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NAC (3 mL, 300 mg)
Number of subjects: 48
Study 30802208 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic NAC (200 mg/kg once daily)
Number of subjects: 48
Study 30802208 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical + Systemic NAC (3 mL, 300 mg topical + 200 mg/kg systemic)
Number of subjects: 48
Study 30802208 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride-treated sterile gauze)
Number of subjects: 48
Study 28058753 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg
Number of subjects: 69
Study 28058753 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg
Number of subjects: 69
Study 28058753 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 2 mg
Number of subjects: 69
Study 26599232 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 155
Study 26599232 — intervention group
Group type: COMPARATOR
Intervention: Pre-admission treatment types
Number of subjects: 155
Study 23741491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling and motivational interviewing according to the overweight prevention protocol (n = 349)
Number of subjects: 637
Study 23741491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition, n = 288)
Number of subjects: 637
Study 20581702 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable ROM (VROM) training
Number of subjects: 22
Study 20581702 — intervention group
Group type: COMPARATOR
Intervention: Full ROM control (CON)
Number of subjects: 22
Study 18155051 — intervention group
Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral block with 30 mL of mepivacaine
Number of subjects: 48
Study 18155051 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment block with 30 mL of mepivacaine
Number of subjects: 48
Study 16963388 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-session relationship-based STD prevention intervention provided to the couple together
Number of subjects: 217
Study 16963388 — intervention group
Group type: EXPERIMENTAL
Intervention: Same intervention provided to the woman only
Number of subjects: 217
Study 16963388 — intervention group
Group type: COMPARATOR
Intervention: Single-session education control provided to the woman only
Number of subjects: 217
Study 15577438 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel (40-120 mg/m2/cycle for the first 10 patients, 100 mg/m2/cycle for the subsequent 13 patients)
Number of subjects: 23
Study 15577438 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel
Number of subjects: 23
Study 10811493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with carboplatin AUC 7 every 28 days for six courses (n = 81)
Number of subjects: 162